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CI = confidence interval; EBV = Epstein-Barr virus; FEV1 = forced expiratory volume in 1 second; NNT = number needed to treat; PaO2 = arterial
partial pressure of oxygen; RR = relative risk; SARS = severe acute respiratory syndrome.
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Abstract
Traditional teaching suggests that corticosteroids should be
avoided during acute infectious episodes for fear of compromising
the immune response. However, the outcome benefit shown
through steroid administration in early septic shock implies this
paranoia may be misplaced. We therefore performed a systematic
review of the literature to identify the current strength of evidence
for the use of corticosteroids in specified infections, and to make
appropriate graded recommendations.
Introduction
Traditional teaching suggests that corticosteroids impair the
ability of the body to fight infection and that this may prove
catastrophic if an appropriate antibiotic is not chosen. In
recent years, however, the early use of steroid therapy has
become progressively established in a wide range of infective
conditions [1,2], including septic shock, its most severe
systemic manifestation. We thus decided to conduct a
systematic review of the literature to identify the current
strength of evidence for the use of corticosteroids in specified
infections, and to make appropriate graded recommendations.
Methodology
The Cochrane Database of Systematic Reviews, the
Database of Abstracts of Reviews of Effects (DARE) and the
Cochrane Central Register of Controlled Trials (CENTRAL)
(issue 1, 2005) were searched using medical subject
headings (MeSH) for steroids, glucocorticoids, adrenal cortex
hormones AND (virus diseases OR bacterial infections OR
mycoses). In addition, phase 1 of the Cochrane highly
sensitive strategy for randomised controlled trials [3] AND a
steroid search (Table 1) AND search terms for specific
clinical entities were utilised in both MEDLINE and EMBASE.
Systematic reviews published since 1999 formed the
mainstay of analysis. Trials published more recently, or not
considered by the reviews, were also included. For infections
with no prior review, original articles are summarised. The
abstracts thus obtained were scanned for relevance, and the
original papers retrieved. Specific clinical entities are
reviewed in order of the strength of evidence, proceeding
through meta-analyses of multiple well-controlled trials to
single small studies and case reports.
Table 2 shows the systems used to grade the level of
evidence and consequent level of recommendation for the
use of corticosteroids for each specified infection.
Conditions
Septic shock
The use of steroids in septic shock has been the subject of
controversy for five decades. The lack of benefit reported by
two large multi-centre randomised trials [4,5] prompted two
meta-analyses published in 1995 [6,7] to recommend that
short courses of high dose steroids should no longer be used
in patients with the sepsis syndrome. Subsequent studies in
a sicker septic population, however, reported either survival
benefit or reduction in catecholamine requirements with
longer courses (≥5 days) of lower stress doses of cortico-
steroids (200 to 300 mg hydrocortisone daily equivalent) [8].
This strategic shift to an ‘adrenal replacement’ dose (albeit
the doses chosen will still generate supra-physiological
levels) arose from the recognition that relative adrenal
insufficiency was a common phenomenon in sepsis and a
poor prognostic factor. A rebound increase in plasma
cytokine levels at three days [9] prompted the recommen-
dation that the steroid dose should be tailed off rather than
stopped abruptly.
In view of the above, a recent Cochrane systematic review
and accompanying publication re-examined the use of
corticosteroids in septic shock [10,11]. Although there was
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no overall outcome benefit, subgroup analysis of trials using
low dose steroids did show a significant reduction in 28 day
mortality (relative risk (RR) 0.8 (confidence interval (CI) 0.67
to 0.95)), hospital mortality (RR 0.83 (CI 0.71 to 0.97)) and
shock reversal at both 7 days (RR 1.6 (CI 1.01 to 2.01)) and
28 days (RR 1.21 (CI 1.04 to 1.52)).
The largest study contributing to this subgroup analysis is
worthy of individual consideration [8]. Although contributing
27% weight to the review, this trial only demonstrated
significant mortality reduction in a subgroup of patients
showing a subnormal rise in plasma cortisol (<9 µg/l
(248 nmol/l)) in response to stimulation by 250 µg
tetracosactrin (synthetic adrenocorticotropic hormone (ACTH)).
Some have since argued that all septic shock patients should
receive corticosteroids regardless of tetracosactrin response
on the grounds of lack of harm [12], whereas others counsel
caution in view of the risk of potential adverse events such as
myopathy [13]. A large multicentre European study
(CORTICUS) is shortly to conclude and will hopefully provide
more definitive data. Until then, we believe that steroids
should be used only in tetracosactrin non-responders.
Recommendation 1
Low dose (200 to 300 mg) hydrocortisone equivalent/day for
7 days should be given to patients with a subnormal cortisol
response (<9 µg/l (248 nmol/l)) following 250 µg tetracosactrin.
Grade of evidence I; grade of recommendation B.
Recommendation 2
Hydrocortisone can be started pending the laboratory results
and discontinued if the rise in cortisol level following 250 µg
tetracosactrin exceeds 9 µg/l.
Grade of evidence I; grade of recommendation B.
Recommendation 3
After the seven day course, the dose of corticosteroid should
be tailed off over a further five to seven days.
Grade of evidence IV; grade of recommendation E.
Acute bacterial meningitis
A recent systematic review performed a per-protocol analysis
of 1,853 (89%) of 2,064 enrolled patients, of all age groups,
Table 1
Steroid search terms used in MEDLINE and EMBASE
1 SEARCH: STEROI$ 
2 SEARCH: CORTICO$ 
3 SEARCH: GLUCOCORT$ 
4 SEARCH: CORTIS$ 
5 SEARCH: HYRDOCORTISONE 
6 SEARCH: HYDROCORTISOL
7 SEARCH: PRED$ 
8 SEARCH: METHYLPRED$ 
9 SEARCH: METHYL ADJ PRED$ 
10 SEARCH: DEXAMET$ 
11 SEARCH: BECLOMET$ 
12 SEARCH: BUDESON$ 
13 SEARCH: TRIAMCIN$ 
14 SEARCH: FLUTIC$ 
15 SEARCH: 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 
OR 10 OR 11 OR 12 OR 13 OR 14
Table 2
Grading system
Grading of recommendations A Supported by at least two level I investigations 
B Supported by one level I investigation 
C Supported by level II investigations only 
D Supported by at least one level III investigation 
E Supported by level IV or V evidence 
Grading of evidence I Evidence is based on randomised controlled trials (or meta-analysis of such trials) of adequate size to 
ensure a low risk of incorporating false-positive (alpha) or false-negative (beta) results
II Evidence is based on randomised controlled trials that are too small to provide ‘level I’ evidence. 
They may show either positive trends that are not statistically significant or no trends and are 
associated with a high risk of false-negative results
III Evidence is based on non-randomised controlled or cohort studies, case series, case-control studies 
or cross-sectional studies
IV Evidence is based on non-randomised, historical controls and expert opinion
V Evidence is based on case series, uncontrolled studies, and expert opinion Page 3 of 10
(page number not for citation purposes)
from 18 identified trials [14]. Corticosteroid therapy
consisted of either dexamethasone (0.4 to 0.9 mg/kg),
hydrocortisone, prednisolone, or a combination. The mortality
rates with and without steroid therapy were 8.5% and 11.6%,
respectively, providing a number needed to treat (NNT) of 33
to save one life. This increased to 280 in the subset of 742
children (steroid group mortality 6.2%, placebo 6.6%) but fell
to 10 in adult patients (8% steroid, 17.8% placebo). The
authors exercised caution over the adult data analysis due to
methodological concerns over one major trial included.
The causative organism appeared important in determining any
outcome benefit from steroids. Significant benefit was found
when treating Streptococcus pneumoniae and “species other
than Haemophilus influenzae”, though statistical significance
was also not achieved with Neisseria meningitides infection.
Hearing loss was significantly reduced (2.7% steroids, 7.7%
control), providing a NNT of 20. The NNT was lowered to 15
in children (2.9% steroid, 9.8% control) where benefit was
seen regardless of causative organism. Long-term neuro-
logical sequelae were reduced overall, but this did not
achieve significance when age group or organism subset
analyses were performed. A non-significant increase in
gastrointestinal bleeding was noted, otherwise there were no
associated adverse effects. A greater risk reduction occurred
if steroid was given with or before the start of antibiotics. On
the basis of this review, the authors recommend a regimen of
dexamethasone 0.6 mg/kg daily for four days, started
preferably before antibiotic therapy.
A recently published study of 301 adult patients with
bacterial meningitis adds further support to these findings
[15]. Those randomised to receive dexamethasone showed
an absolute reduction in death or disability from severe to
moderate both overall (NNT 10) and in the S. pneumoniae
subgroup (NNT 4). Statistical significance was not, however,
achieved in reduction of neurological sequelae, including
hearing loss. The authors recommend a dose of 10 mg
dexamethasone qds for 48 hours, starting before antibiotic
therapy [16], though reservations have been raised about this
regimen for meningitis not caused by pneumococcus, and in
the setting of sepsis [17].
The population setting may be of importance. A large
randomised trial of paediatric meningitis in a developing
country with late presentation of disease, high levels of
resistance to available antimicrobials, and a higher prevalence
of chronic disease and malnutrition demonstrated no effect
either on survival or neurological sequelae [18,19].
Recommendation
Dexamethasone 10 mg qds or equivalent should be given for
48 hours, preferably commencing prior to antibiotic therapy.
Grade of evidence I; grade of recommendation A.
Pneumocystis pneumonia
Patients with Pneumocystis jiroveci  pneumonia may suffer
deterioration in pulmonary function after initiation of anti-
microbials. The efficacy of adjunctive corticosteroid therapy in
avoiding this complication was investigated, leading to a
consensus statement recommending its use in HIV positive
adolescents or adults with moderate or severe disease [20].
If the arterial partial pressure of oxygen (PaO2) is <9.3 kPa or
the alveolar-arterial gradient >4.7 kPa, steroids should be
started, preferably within 72 hours of admission.
A randomised, non-blinded trial of prednisolone versus
placebo in 251 HIV positive patients, mainly with confirmed
Pneumocystis pneumonia, revealed a significant mortality
reduction at 31 and 84 days [21]. The likelihood of the
combined endpoint of respiratory failure (defined as death,
mechanical ventilation or a PaO2:FiO2 ratio <10 kPa) was 2.3
times more common among eligible non-steroid treated
patients. The NNT was 29 to gain benefit. Adverse effects
included a significant increase in herpes reactivation, and
possibly more oral thrush.
Adjunctive steroid has previously been shown to prevent early
deterioration of Pneumocystis pneumonia patients [22,23],
though not to hasten recovery [24]. Hence, steroids may not
hasten recovery, but may avoid acute deterioration in a group
of patients [25].
Recommendation
Prednisolone 40 mg twice daily for 5 days, then 40 mg daily
for 5 days, then 20 mg daily for 10 days should be given to
adult patients with PaO2 <9.3 kPa or alveolar-arterial gradient
>4.7 kPa.
Grade of evidence I; grade of recommendation A.
Community acquired pneumonia
In a small, recently published, multicentre trial, 46 patients
with severe community-acquired pneumonia randomised to
receive hydrocortisone (200 mg bolus followed by 10 mg/h
infusion for 7 days) showed significant improvements in gas
exchange, resolution of organ failure and reduction in hospital
stay [26].
Recommendation
Hydrocortisone (200 mg bolus followed by 10 mg/h infusion
for 7 days) may be considered in severe community-acquired
pneumonia.
Grade of evidence II; grade of recommendation C.
SARS-related pneumonia
Corticosteroid therapy (methylprednisolone or hydro-
cortisone) was routinely used during the outbreak of the
coronavirus-associated severe acute respiratory syndrome
(SARS) following early anecdotal reports of benefit. The rapid
Available online http://ccforum.com/content/10/1/203emergence of the syndrome prevented the establishment of
randomised controlled trials. Two subsequent retrospective
reviews [27,28] from two different Hong Kong hospitals
produced conficting results. One claimed greater benefit
from initial therapy with pulse steroid methylprednisolone
(≥500 mg/day) in terms of supplemental oxygen
requirements and better radiographic outcomes, though the
need for intensive care unit admission, mechanical
ventilation, and mortality rates were similar. The other study,
however, reported that corticosteroid use was associated
with a doubling in adverse outcomes (37.9% versus 16.7%)
and a 20.7-fold increase in risk of either intensive care unit
admission or mortality, independent of age and disease
severity.
Recommendation
Steroids cannot be recommended for treatment of SARS-
related pneumonia.
Grade of evidence V; grade of recommendation E.
Bronchiolitis and viral wheeze
Viral bronchiolitis, usually due to respiratory syncytial virus, is
a leading cause of respiratory failure in infants. A systematic
review of randomised, controlled trials in mechanically
ventilated infants totalling 140 patients found no significant
decrease in the duration of ventilation or hospital admission
with systemic dexamethasone [29]. Other trials have shown
benefit with steroids, with a reduction in hospital stay in non-
ventilated infants [30,31], and in the need for hospital
admission for children presenting with bronchiolitis to the
emergency room [32].
Cough and wheeze are common long-term sequelae of
bronchiolitis. Nebulised budesonide given early did not
significantly affect one-year outcome in 161 infants [33]. No
difference was also seen in time to discharge, re-admission
rates, survival, or visits from a general practitioner, reflecting
findings made by other groups [34,35].
The use of inhaled steroid for episodic viral wheeze of
childhood did not reduce symptom severity, duration, or the
need for hospital admission [36].
Recommendation 1
Steroids should not be used in children with bronchiolitis who
are ventilated.
Grade of evidence II; grade of recommendation C.
Recommendation 2
Steroids should be given to children with mild bronchiolitis or
viral wheeze who present as outpatients. The best regimen is
as yet undetermined.
Grade of evidence II; grade of recommendation C.
Croup
A Cochrane review of 24 studies involving 2,878 patients
comparing any glucocorticoid to placebo demonstrated
significant benefit from a single dose [37]. Position on a
validated croup scale was likely to be reduced, with a RR of
re-admission to hospital of 0.5 (0.4 to 0.7; NNT 17), and a
reduction in length of stay of 12 (5 to 19) hours. There was,
however, no significant difference in the number of children
requiring intubation.
Recommendation
Steroids should be administered to children with croup. The
optimal dose and route are yet to be defined.
Grade of evidence I; grade of recommendation A.
Tuberculous meningitis
Tuberculous meningitis carries a high mortality. Steroids have
been used as adjunctive treatment since the 1950s yet, even
so, mortality is still around 20% to 30%, with neurological
sequelae common in survivors.
A review of six studies totalling 595 patients with mild to
severe disease showed a mortality reduction with steroids
(RR 0.79 (CI 0.69 to 0.97), NNT 14) [38]. Analysis by age
suggested risk reduction only for those under 15 years old,
although the total number of adults recruited was small.
Mortality for mild disease was too rare to allow analysis. HIV
status was not recorded in the trials analysed. There was
considerable heterogeneity in the recording of adverse
events and neurological sequelae. No study gave evidence of
optimal treatment concealment. A funnel plot was suggestive
of publication bias. Hence no firm recommendation could be
given without further evidence.
A recent trial involved 545 patients over age 14 from Vietnam
with definite or probable tuberculous meningitis who were
randomised to receive four weeks of tapering intravenous
dexamethasone followed by four weeks of oral therapy, starting
at 0.4 mg/kg for non-mild disease, and 0.3 mg/kg in mild cases
[39,40]. At nine months the steroid group showed an absolute
risk reduction in mortality of 9.2% over placebo (NNT 11).
There was no significant reduction for death and severe
disability combined, perhaps because of the study power, or
the way in which disability was measured. HIV infection was
associated with higher mortality, but no effect of steroid was
seen in this subgroup. Adverse events were lower in the steroid
group, particularly those that led to a change in anti-
tuberculous therapy, such as drug-induced hepatitis. As a
change in therapy was associated with death, this is a possible
mechanism for the mortality reduction effect of steroids.
Recommendation
Dexamethasone tapering over four weeks, from 0.4 mg/kg or
0.3 mg/kg depending upon severity, should be administered
for tuberculous meningitis.
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Tuberculous pericarditis
A review of four trials involving 469 patients showed a trend
to reduced mortality and persistence of disease [41].
Statistical significance for a reduced mortality was only
reached for those with tuberculous effusion (RR 0.48 (CI
0.29 to 0.8)), but this significance was lost on intention-to-
treat analysis. Subgroup analysis of HIV positive individuals
did not show significant results.
A recent randomised trial of 383 South African patients
stratified patients by disease type, namely constrictive,
effusive with drainage, or effusive with conservative
management [42]. The effect of prednisolone on mortality,
functional status and need for repeat pericardiocentesis was
studied. The prednisolone group showed a trend towards
improved overall survival, but it did significantly decrease the
composite endpoint of death and adverse outcome (NNT 5),
mainly as it reduced the need for pericardectomy and its
associated mortality. Upon correction for age and gender,
deaths from tuberculous pericarditis were significantly
reduced. There was no significant effect on functional status
at 10 years.
Recommendation
Prednisolone tapering from 60 mg daily (adult dose) over
11 weeks should be given in tuberculous pericarditis.
Grade of evidence I; grade of recommendation A.
Tuberculous pleurisy
Three small trials investigating the use of steroids in
tuberculous pleurisy were analysed in a systematic review
[43]. These were not scaled to measure mortality, thus
steroids were not recommended on this basis. Significance
was not reached for reduction of symptomatology in the
acute phase, or reduced pleural sequelae.
A more recent trial of 197 HIV positive patients with pleural
tuberculosis showed no significant reduction in mortality, a
non-significant increase in recurrence, and a higher rate of
Kaposi sarcoma in the steroid-treated group [44]. Hence
there can as yet be no recommendation for the use of
steroids in this group, and the evidence is still lacking for non-
HIV infected individuals.
Recommendation 1
Steroids should not be given for tuberculous pleurisy in HIV
positive patients.
Grade of evidence I; grade of recommendation B.
Recommendation 2
Steroids cannot yet be recommended for tuberculous
pleurisy in non-HIV positive patients.
Grade of evidence II; grade of recommendation C.
Pulmonary tuberculosis
Various clinical and other indices were improved by the use
of steroids in pulmonary tuberculosis according to a review of
11 studies [45]. Significant improvement was seen in time to
defervescence, weight gain, hospital stay and inflammatory
markers. X-ray appearances, both for infiltration and
cavitation, were faster to resolve. Sputum smear or culture
positivity was not altered. The heterogeneity of these studies
did not enable the reviewers to perform overall statistical
analysis. It should be borne in mind, however, that most of
these studies predate 1970 and were conducted before the
advent of rifampicin. The results should thus be treated
cautiously.
Systemic steroid therapy has also been suggested to
improve bronchoscopic and radiographic resolution of
tuberculous bronchial obstruction in children in randomised
studies of 117 and 29 patients [46,47].
A recent study in HIV-associated tuberculosis [48], however,
suggested that the benefits of prednisolone therapy on
immune activation and CD4(+) T cell counts did not outweigh
the risks of adverse events (a transient increase in HIV RNA
levels, worsening of underlying hypertension, fluid retention
and hyperglycemia).
Recommendation
Steroids may be considered for patients with pulmonary
tuberculosis, particularly those with extensive disease, but not
in HIV-positive patients.
Grade of evidence II; grade of recommendation C.
Chronic obstructive pulmonary disease
Ten randomized controlled trials, totalling 951 patients, of
different regimens of systemic steroids for exacerbations of
chronic obstructive pulmonary diseases were recently
analysed [49]. The primary endpoint was treatment failure
defined as the need for extra or repeated treatment of the
exacerbation, or mortality. Steroids reduced this risk (odds
ratio 0.48 (CI 0.34 to 0.68), NNT 9) but no difference was
seen in mortality. There was improvement in breathlessness,
and in measures such as forced expiratory volume in
1 second (FEV1) and arterial blood gas tests. Hospital stay
was not reduced, possibly due to heterogeneity of discharge
policy and co-morbidity. Adverse events were more likely with
the number needed to harm being 6 overall, and 13 for
hyperglycaemia. A further review confirmed a reduction in
treatment failure and also a reduced length of hospital stay
[50]. This review suggested that two weeks of steroid
therapy was as effective as eight, with less associated
infection risk. Long-term inhaled steroids also reduced the
risk of acute exacerbation in a subgroup of patients with FEV1
<2L (RR 0.75 (CI 0.71 to 0.8)) [51].
Available online http://ccforum.com/content/10/1/203
Page 5 of 10
(page number not for citation purposes)Recommendation
Short course oral steroid should be given for exacerbations of
chronic obstructive pulmonary disease. This may be in the
form of 30 mg prednisolone daily for 14 days.
Grade of evidence II; grade of recommendation C.
Cystic fibrosis
A review of 10 trials of inhaled steroids in cystic fibrosis did
not find any difference in lung function testing, or the number
of days treatment with antibiotics [52].
Recommendation
Inhaled steroids should not be administered routinely in cystic
fibrosis patients.
Grade of evidence II; grade of recommendation C.
Chronic hepatitis B
A systematic review found 13 adequate trials of steroid
therapy prior to interferon-α involving 790 patients [53]. Pre-
treatment with four to six weeks of steroids showed improved
clearance of markers of infection such as hepatitis e antigen
and hepatitis B DNA. There was, however, no difference in
mortality, hepatitis B surface antigen, hepatitis B e antibody,
liver histology, or quality of life. Adverse events were equally
distributed. The authors concluded that recommendation
would require an improvement in clinical outcome that was
not seen.
Recommendation
Steroids should not be used for pre-treatment of chronic
hepatitis B.
Grade of evidence II; grade of recommendation C.
Chronic hepatitis C
A review found eight randomised trials that examined
corticosteroids in chronic hepatitis C [54]. Protocols and
patient groups showed significant heterogeneity, with use of
steroid alone or in combination with interferon, and
comparison against placebo or interferon. There was no
effect on all-cause or liver-related mortality, virological
response, biochemistry, or liver biopsy findings. One trial
reported a significant reduction in side-effects of interferon
with concurrent steroid use.
Recommendation
Steroids should not be used for treatment of chronic hepatitis C.
Grade of evidence II; grade of recommendation C.
Acute viral hepatitis
A trial involving 300 patients with acute viral hepatitis studied
methylprednisolone tapering from 48 mg daily over 12 weeks
[55]. There was no benefit with steroids. Indeed, there was a
non-significant trend towards increased mortality. Hospital
stay, time to symptom resolution, and most biochemical
markers were unaffected.
Recommendation
Steroids should not be used for treatment of acute viral
hepatitis.
Grade of evidence II; grade of recommendation B.
Idiopathic facial nerve (Bell’s) palsy
A review considered 4 trials, with 179 patients [56]. There
was no improvement in recovery of motor function, or
presence of synkinesis or autonomic dysfunction. This result
is at odds with previously published analyses, which have
recommended steroids. The authors note that prior analyses
include a study with a loss to follow up of 29%, and that
significance is lost with the exclusion of this trial.
Recommendation
Steroids should not be used to treat Bell’s palsy.
Grade of evidence II; grade of recommendation C.
Malaria
Adjunctive steroid has been used to improve mortality and
neurological sequelae, both of which are common.
A review found two adequate trials with a total of 143
patients [57]. Mortality did not improve with dexamethasone.
Trials so far have been too small, however, to exclude an
effect. One study suggested that steroid use increases the
time to recovery from coma and, therefore, may be
detrimental [58]. Hence there can be no recommendation
thus far.
A small trial of steroid in treating nephrotic syndrome as a
result of plasmodium malaria found there to be no reduction
of proteinuria [59].
Recommendation 1
Steroids should not be used to treat cerebral malaria.
Grade of evidence II; grade of recommendation C.
Recommendation 2
Steroids should not be used to treat nephrotic syndrome
secondary to malaria.
Grade of evidence II; grade of recommendation C.
Typhoid
A case control study of 374 blood culture confirmed severe
typhoid cases in Papua New Guinea found that 400 mg hydro-
cortisone 6 hourly for 12 doses did not improve mortality [60].
This finding is in contrast to earlier randomised studies [61].
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3 mg/kg followed by 1 mg/kg for a further 8 doses gave a
case fatality of 2/20 for steroid treatment versus 10/18 for
placebo (NNT of 3) [62]. The investigators later published a
case control series of 41 patients with similar mortality
reduction. A partially blinded trial of steroids as adjunct to
surgery in typhoid perforation gave a similar mortality
reduction, again with trial numbers being small [63].
Given the dramatic reduction in mortality, steroids have been
recommended in higher dose for severe typhoid, particularly
with shock, delirium, or coma, after the exclusion of other
bacterial meningitis (but see above).
Recommendation
Steroids should be used in severe typhoid.
Grade of evidence II; grade of recommendation C.
Septic arthritis
The effect of adjuvant dexamethasone compared to anti-
biotics alone was studied in one randomized controlled trial
[64]. Children aged between 3 months and 13 years with a
diagnosis of septic arthritis were given either placebo or
0.2 mg/kgdexamethasone for four days from diagnosis.
The steroid group had significantly less joint dysfunction at
the time of finishing treatment (2/50 versus 16/50; NNT 4), at
6 months (1/50 versus 19/50; NNT 3) and 12 months follow
up (1/50 versus 13/50; NNT 5). Details were not given of
adverse events related to steroid use. Residual dysfunction
seemed more likely with Staphylococcus aureus infection, but
trial numbers precluded subgroup analysis.
Recommendation
Dexamethasone 0.2 mg/kg for 4 days should be given for
haematogenous septic arthritis.
Grade of evidence II; grade of recommendation C.
Dengue shock syndrome
In the absence of a specific antiviral agent, high doses of
glucocorticoid and fluid rehydration have been used to treat
Dengue shock syndrome. Steroid use has been supported by
an early study of 98 patients. [65]. This finding has not been
confirmed with more recent trials, there being no case fatality
difference amongst the 97 and 63 children randomised in each
study [66,67]. One caveat is that the observed mortality rate
was lower than expected, thus under-powering the trials, and
leaving the possibility of a steroid effect. Steroids cannot yet be
recommended on this basis for Dengue shock syndrome.
Recommendation
Steroids should not be used for Dengue shock syndrome.
Grade of evidence II; grade of recommendation C.
Infectious mononucleosis
One recent trial of single dose dexamethasone 0.3 mg/kg
administered to adolescents with suspected Epstein-Barr virus
(EBV) pharyngitis gave improved pain score on visual analogue
scale at 12 hours but not thereafter [68]. An earlier trial
combining acyclovir with prednisolone had no effect on either
the duration of clinical symptoms or the development of EBV-
specific cellular immunity [69]. A further non-randomized study
of 22 patients with impending airway obstruction demonstrated
more rapid clinical improvement with steroid, although none of
the control group actually developed airway obstruction [70].
Recommendation
Steroids may be of benefit in infectious mononucleosis if
there is respiratory compromise or severe pharyngeal oedema.
Grade of evidence II; grade of recommendation C.
Bordatella pertussis
A review found only one randomized trial of steroid use in
whooping cough in infants, with only seven trial participants,
leading to a non-significant effect on cough reduction or
duration of hospital stay [71].
Recommendation
Steroids should not be administered for whooping cough in
infants.
Grade of evidence II; grade of recommendation C.
Leprosy
Steroids are recommended by the WHO for new nerve
damage in leprosy [72]. This recommendation is, however,
based on expert opinion and a recent review highlighted a lack
of controlled trials [73]. Case series have demonstrated
improved nerve function in up to 88% of ambulatory patients
after 40 mg prednisolone daily for 12 to 20 weeks. A recent
trial of prophylactic 20 mg prednisolone daily to prevent
reversal reaction after treatment resulted in a significant
reduction in nerve damage at 4 months, but no statistically
significant change at 12 months (albeit a 23% relative
decrease) [74]. A trial of higher dose prednisolone, tapering
from 40 mg daily over 16 weeks, for established impaired nerve
function did not show any greater likelihood of improvement
compared with placebo among the 95 people enrolled [75].
Recommendation 1
Prednisolone 40 mg daily for 12 to 20 weeks should be used
to treat reversal reaction causing new nerve function impair-
ment in leprosy.
Grade of evidence II; grade of recommendation C.
Recommendation 2
Steroids should not be used as prophylaxis for leprosy
reversal reaction.
Available online http://ccforum.com/content/10/1/203
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Recommendation 3
Steroids should not be used to treat established impaired
nerve function in leprosy.
Grade of evidence II; grade of recommendation C.
Onchocerciasis
Onchocerca volvulus microfilariae are usually treated with
ivermectin. When diethlycarbamazine is used there is a
significantly increased chance of reaction to the lysed
microfilariae. This Mazzotti reaction comprises itching, rash,
fever, tachycardia and hypotension, and is sometimes fatal. A
small trial of 40 patients demonstrated that the cardio-
vascular, but not cutaneous, aspects of this reaction could be
alleviated by the use of three days of prednisolone 20 mg
three times daily [76,77].
Recommendation
Prednisolone 60 mg daily for 3 days should be used in
treating the Mazzotti reaction.
Grade of evidence II; grade of recommendation C.
Cysticercosis
In patients with solitary granuloma stage neurocysticercosis,
a small trial of 108 patients has suggested that 1 mg/kg
prednisolone for 10 days after the new onset of seizures, as
well as anti-epileptic medicine, may result in a higher chance
of lesion resolution, and a higher chance of remaining seizure
free [78].
Recommendation
Prednisolone 1 mg/kg for 10 days should be used to treat
solitary granuloma stage neurocysticercosis.
Grade of evidence II; grade of recommendation C.
Conclusion
We present a synthesis of the diverse evidence related to
steroid use in infections. A more detailed consideration of the
applicability of steroids can be found in some condition-specific
reviews, many of which are cited above. The conditions we have
covered range widely in severity, duration, site, and type of
causative organism. Furthermore, the dosing and duration of
steroid therapy varies enormously between conditions and, as
clearly illustrated by steroid use in sepsis, benefit or harm may
accrue depending on the regimen used. In many of the
conditions listed, only limited data are available. There is an
obvious need to have more adequately powered trials to provide
definitive evidence of benefit or harm, and a better
understanding of how steroids modulate disease processes.
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